India Pharma Exports Hit a Record. So Why Was the 2030 Target Cut?
Pharmexcil now sees $80-90 billion by 2030, not $130 billion. Tariffs and shipping, not demand, explain the gap.
India pharma exports hit a record $31.1 billion in FY26. Yet Pharmexcil has cut the industry's 2030 target from $130 billion to $80-90 billion. The reason is not weak demand. US tariff uncertainty and Middle East shipping trouble have made exports costlier and harder to plan. Shipments to the US fell nearly 10% to about $9.5 billion.
India pharma exports crossed $31 billion in FY26. That is a record. Yet the industry's own export body just cut its 2030 goal by about a third. Both things are true at once. The gap between them says a lot about where this sector is headed.
What Pharmexcil Actually Said
Namit Joshi chairs the Pharmaceuticals Export Promotion Council of India (Pharmexcil). In April 2025, the industry set a goal of $130 billion in sales by 2030. Joshi now expects $80 billion to $90 billion instead.
His reason was blunt. "Given the geopolitical changes, the Middle East crisis and everything, I don't foresee us achieving that growth target," he said.
Note what is missing from that list. Demand. Nobody expects the world to need fewer medicines. The problem is what it now costs to ship them and how hard that is to plan.
A Record Year That Still Missed the Mark
India's pharma market was worth about $60 billion in the year to March 2026. Exports made up $31 billion of that. Domestic sales made up $29 billion.
| Metric | FY25 | FY26 |
|---|---|---|
| Total pharma exports | $30.4 billion | $31.1 billion (record) |
| Exports to the US | about $10.5 billion | about $9.5 billion |
| US share of exports | about 35% | about 30% |
The US market shrank while the total still grew. Brazil, Europe and Africa took up the slack. Growth of just over 2% is thin. But it is growth, with the largest buyer in decline.
Why the US Decides India's Pharma Numbers
One number gets misread all the time. Generics make up about 90% of all prescriptions filled in the US. But those are all generics from every country. Not India's alone.
India's own share is still huge. Indian firms fill close to half of every generic script in the US.
Here is the catch. Generics are cheap. India's share of the value of US generic imports is nearer 30%. So India ships a lot and earns little. A tax on volume then hurts more than the sales figure hints.
Risk also differs by firm. In FY26, the US made up roughly 30% of Sun Pharma's revenue, about 44% of Zydus Lifesciences' and about 46% of Aurobindo Pharma's. That spread matters when the tax lands. Worth a check before treating pharma stocks as one basket.
The Tariff Clock: 0%, Then 100%, Then 200%
On 22 July 2026, US President Donald Trump set out a phased plan for imported generics.
- Duty-free through July 2028, a two-year transition running from 1 August 2026.
- A 100% tariff from August 2028.
- 200% from 2029.
The stated aim is to move plants into the US. Markets did not wait for 2028. The Nifty Pharma index fell close to 2% intraday on the news, then won back part of the drop.
One legal detail matters. These duties would likely ride on Section 232 of the US Trade Expansion Act, which covers national security. That is firmer ground than the trade taxes struck down earlier in 2026. So the threat is not idle. SAHI tracked the first market reaction when the plan broke.
Under the July 2026 US plan, when does the 100% tariff on imported generic medicines begin?
Why Shifting Plants to America Is Not the Fix
Building in the US looks like the easy answer. The maths says no.
Land, labour, power and rules all cost more there. Generic margins are thin to start with. A plant also takes years. Firms need land, then a build, then testing, then sign-off from the FDA.
Pharmexcil puts it at five years or more to rebuild a full pharma supply chain inside the US. The taxes begin in 2028. Those dates do not line up.
The API Gap Nobody Is Pricing In
The plan covers finished generics. It says little about Active Pharmaceutical Ingredients, or APIs. These are the raw chemicals that go into a pill.
That silence is the biggest hole in the plan. About 80% of the APIs used by India's drug firms come from China. And for 83 of the top 100 generic drugs sold in the US, there is no US source of the API at all.
So a new US plant would still buy its raw inputs, most likely from China. Whether APIs get taxed later will decide how much really shifts.
Roughly what share of the Active Pharmaceutical Ingredients used by Indian drugmakers comes from China?
Three Things Investors Get Wrong Here
- Treating 2028 as far away. Supply deals with US buyers are signed years ahead. Price talks for the tax years start well before the tax does.
- Reading the US fall as lost demand. Pharmexcil blames the FY26 dip on a high base, price cuts in generics and buyers running down stock. Those things pass.
- Treating pharma as one trade. A firm earning 46% of sales from the US is not the same bet as one earning 30%. The wider India-US trade picture cuts each name a bit differently.
What to Watch Next
Pharmexcil expects 6-10% annual growth over the next three years. Double-digit growth can follow if the high-value lines deliver.
Those lines are the real story. Biosimilars, peptides, complex generics, injectables and speciality drugs all earn better margins than plain generics. Patents in the GLP-1 class start to lapse soon, and Indian firms are already lining up for it.
The other shift is on the map. Europe, Japan, Latin America and Africa are all being pushed harder. FY26 showed that this works. But none of it is quick. That is exactly why the 2030 number moved.
Sources: Pharmaceuticals Export Promotion Council of India (Pharmexcil) FY26 export data and chairman's statements; NSE Nifty Pharma index data; the US announcement of 22 July 2026; company FY26 results. Figures as of August 2026.
Frequently Asked Questions (FAQs)
All topics
Click the link, confirm the box next to sahi.com is checked — ignore any other results.